The Transparency Commission of the French National Health Authority has issued a positive opinion for the reimbursement and hospital listing of Iluvien.

The intravitreal implant, developed by Alimera Sciences for the treatment of diabetic macular oedmea (DME), has completed two Phase III clinical trials and demonstrates an improvement in best-corrected visual acuity (BVCA) and an increase in ETDRS eye chart letters.

Professor Gisele Soubrane, clinical investigator for Iluvien, commented, “The Iluvien implant features a sustained-release of the active pharmaceutical agent for up to 36 months, which is in balance with the insidious progression of macular oedema due to long-term diabetes mellitus. The clinical results of the trials were significant; Iluvien provides a new, effective mode for achieving vision improvement."

Dan Myers, Alimera's president and chief executive officer, stated, "We are pleased to receive the CT's positive opinion for reimbursement of Iluvien. We believe this opinion will help us in our discussions with the CEPS pricing committee as we work to make Iluvien available to those suffering from chronic DME in France."